Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations With High Risk for EOS
Shandong University
50 participants
Sep 30, 2023
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.
Eligibility
Inclusion Criteria3
- Patients over 18 years old;
- Pregnant women whose baby are at high risk of developing early-onset sepsis after birth have indications to use preventive or therapeutic antibiotics, and the antibiotics used are PIP/TAZO；
- Patients and their families are fully aware of the research content and sign the informed consent form.
Exclusion Criteria4
- Intolerance or serious adverse reactions to antibiotic use;
- Patients who stopped using PIP/TAZO more than 24 hours before delivery;
- Receiving other systemic trial drugs;
- There are other factors that the researchers think are not suitable for inclusion
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06076200